The Association for Molecular Pathology’s AMP Group released draft guidelines for interpreting and reporting cancer sequencing variants, adding language on biomarkers for therapy response, liquid biopsy reporting, and mutational signatures such as TMB, MSI and HRD. The draft aims to harmonize clinical reporting across labs and give clinicians clearer actionability thresholds. Separately, AMP’s conference preview highlighted AI diagnostics as a major focus, with sessions on algorithmic pathology applications, validation challenges and regulatory readiness. Together these developments signal the field’s parallel push to standardize variant interpretation while integrating AI tools into diagnostic workflows — a dual pressure on labs to upgrade bioinformatics, validation and regulatory documentation.